Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Future Medicine Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Introduction: The case of a patient who developed recurrent delayed immune-related pneumonitis (checkpoint inhibitor pneumonitis [CIP]) after immune checkpoint inhibitor (ICI) therapy for advanced osteosarcoma treatment is presented. Case summary: A 25-year-old female patient with metastatic osteosarcoma was treated with atezolizumab. Grade 2 pneumonitis developed three times in the first two years. Treatment was discontinued after recovery from the last episode of pneumonitis, which was complicated with secondary spontaneous pneumothorax. 2 years after discontinuation of immunotherapy, the patient again developed CIP. Pneumonitis symptoms were regressed with oral steroid therapy during follow-up and a stable disease response continued. Conclusion: Immunotherapy can cause recurrent CIP at any time during the treatment period or after discontinuation of treatment. Plain language summary Immune checkpoint inhibitors have been used in many types of cancer because they cause prolonged tumor responses. However, new side effects associated with these drugs have been identified. Pneumonia of the lung tissue may occur and recur during the use of these drugs or after their discontinuation. Patients with newly developing pulmonary symptoms during follow-up should be carefully monitored for this side effect.
Açıklama
Anahtar Kelimeler
Atezolizumab, Delayed Immune-Related Adverse Events, Immune-Checkpoint Inhibitors, Immunotherapy, Recurrent Pneumonitis, Adverse Events
Kaynak
Immunotherapy
WoS Q Değeri
Q4
Scopus Q Değeri
Q2
Cilt
14
Sayı
6
